Last reviewed · How we verify

Quadrivalent Influenza Vaccine

International Centre for Diarrhoeal Disease Research, Bangladesh · FDA-approved active Small molecule Quality 34/100

This vaccine works by stimulating the body's immune system to produce antibodies against influenza viruses.

The Quadrivalent Influenza Vaccine, developed by the International Centre for Diarrhoeal Disease Research, Bangladesh, currently lacks a strong market position due to the absence of clinical trial data and brand recognition. Its mechanism of stimulating the immune system to produce antibodies against influenza viruses is a standard approach, but it faces significant competition from established brands like Tamiflu, Fluzone High-Dose, and Afluria, which offer specific advantages such as targeted efficacy in older adults or alternative treatment methods. A key risk for the vaccine is the lack of clinical trial data, which may hinder its adoption and regulatory approval, especially in markets where PD-L1 companion diagnostics are required for certain indications. The pipeline outlook remains uncertain without ongoing or planned clinical trials to demonstrate efficacy and safety, which are crucial for gaining a competitive edge in the crowded influenza vaccine market.

At a glance

Generic nameQuadrivalent Influenza Vaccine
Also known asInfluvax Tetra Vaccine, GC3110A, VaxigripTetra™, VaxigripTetra®, QIV
SponsorInternational Centre for Diarrhoeal Disease Research, Bangladesh
Drug classInactivated vaccine
TargetInfluenza viruses
ModalitySmall molecule
Therapeutic areaImmunology
PhaseFDA-approved

Mechanism of action

The Quadrivalent Influenza Vaccine is a type of vaccine that is designed to protect against four different strains of the influenza virus. It contains antigens from two influenza A subtype viruses (A/H1N1 and A/H3N2) and two influenza B viruses. When administered to a person, the vaccine stimulates the body's immune system to produce antibodies against these viruses, providing protection against infection. This is achieved through the activation of immune cells, such as T-cells and B-cells, which recognize and respond to the antigens present in the vaccine.

Approved indications

Common side effects

No common side effects on file.

Drug interactions

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: